Androgen Receptor Variants in Castration-Resistant Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormonal therapies for prostate cancer, which target androgen receptor (AR)-mediated functions, are not curative due to the development of castration-resistant prostate cancer (CRPC) characterized by sustained androgenic signaling that bypasses physiological androgen levels, with limited effective therapeutic options.
Innovation Solution
Identification and characterization of novel AR variants lacking the ligand-binding domain (LBD) but with intact coding potential for the N-terminal domain (NTD) and DNA-binding domain (DBD), which are constitutively active and drive AR signaling independently of androgens, enabling methods for diagnosing, monitoring, and potentially treating prostate cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone deprivation therapies are used to suppress androgen production and binding, then initial clinical regression is achieved, but prostate cancer progresses to castration-resistant phenotype with limited therapeutic options
Solution Approach 1:
The patent segments the androgen receptor protein into different variants (AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, AR-V7) with different domain compositions. By identifying and detecting specific AR variants, the patent enables stratification of patients into different risk groups and treatment responses, allowing for more precise therapeutic approaches rather than uniform hormone deprivation therapy for all patients.
Solution Approach 2:
The patent changes the parameter of AR structure by identifying variants with deletions in the ligand-binding domain (LBD). These structural parameter changes result in constitutively active receptors that cannot be inhibited by conventional hormone therapies, explaining treatment resistance and guiding alternative therapeutic strategies.
2Object-affected harmful factors
If conventional hormone therapies target AR-mediated functions by suppressing androgen production, then initial response is achieved, but sustained androgenic signaling bypasses physiological androgen levels
Solution Approach 1:
The patent extracts and isolates the ligand-binding domain (LBD) as the critical element responsible for androgen-dependent regulation. By identifying AR variants that lack the LBD, the patent demonstrates how the receptor can function independently of androgen binding, explaining the mechanism of therapy resistance and suggesting that targeting the NTD or DBD of AR variants may be effective treatment strategies.
3Measurement precision
If AR variants lacking LBD are identified, then constitutively active signaling is detected, but detection and measurement complexity increases
Solution Approach 1:
The patent creates simplified copy models of AR variants through PCR amplification of specific regions (NTD and DBD) that are characteristic of each variant type. These molecular copies can be detected using standardized techniques such as RT-PCR and immunohistochemistry, reducing the complexity of detecting rare variant transcripts in clinical samples while maintaining high measurement precision.
Data Source
AI summary
The invention features diagnostic and therapeutic methods and compositions featuring androgen receptor variant proteins and nucleic acid molecules whose expression is increased in androgen related diseases or disorders.